Metabolic Syndrome and Risk of Breast Cancer by Molecular Subtype : Analysis of the MEND Study
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved..
BACKGROUND: Metabolic syndrome (MetS) is characterized by a cluster of biological irregularities. The purpose of this analysis was to examine the association of MetS with BC among Nigerian women, and for the first time evaluate this association by molecular subtype.
MATERIALS AND METHODS: MetS was defined as having at least 3 out of 5 of: high blood pressure (≥ 130/85 mm Hg), reduced HDL (< 50 mg/dL), elevated triglyceride (> 150 mg/dL), high waist circumference (≥ 80 cm), and prior diagnosis of diabetes or elevated fasting glucose level (≥ 100 mg/dL). Among 296 newly diagnosed BC cases and 259 healthy controls, multivariable logistic regression models were utilized to estimate adjusted odds ratios (aOR) and 95% confidence intervals (95% CI) for the association between MetS and BC overall. Multinomial logistic regression models were used to evaluate each molecular subtype (Luminal A, Luminal B, HER2-enriched and triple-negative or TNBC).
RESULTS: After adjusting for age, socio-demographic and reproductive risk factors, there was a positive association between MetS and BC (aOR: 1.84, 95% CI: 1.07, 3.16). In stratified analyses, MetS was associated with BC regardless of BMI status; however, the estimate was significant only among normal weight women (aOR: 3.85; 95% CI: 1.25, 11.90). MetS was significantly associated with TNBC subtype (aOR: 4.37, 95% CI: 1.67, 11.44); associations for other molecular subtypes were not statistically significant.
CONCLUSION: MetS appears to be a robust risk factor for BC, particularly for TNBC. Public health and clinical interventions can provide substantial benefits in reducing the burden of MetS and preventing BC among Nigerian women.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Clinical breast cancer - 22(2022), 4 vom: 15. Juni, Seite e463-e472 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Akinyemiju, Tomi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cholesterol |
|---|
| Anmerkungen: |
Date Completed 31.05.2022 Date Revised 10.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clbc.2021.11.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335160018 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335160018 | ||
| 003 | DE-627 | ||
| 005 | 20231225225228.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clbc.2021.11.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335160018 | ||
| 035 | |a (NLM)34980540 | ||
| 035 | |a (PII)S1526-8209(21)00320-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Akinyemiju, Tomi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metabolic Syndrome and Risk of Breast Cancer by Molecular Subtype |b Analysis of the MEND Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.05.2022 | ||
| 500 | |a Date Revised 10.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Metabolic syndrome (MetS) is characterized by a cluster of biological irregularities. The purpose of this analysis was to examine the association of MetS with BC among Nigerian women, and for the first time evaluate this association by molecular subtype | ||
| 520 | |a MATERIALS AND METHODS: MetS was defined as having at least 3 out of 5 of: high blood pressure (≥ 130/85 mm Hg), reduced HDL (< 50 mg/dL), elevated triglyceride (> 150 mg/dL), high waist circumference (≥ 80 cm), and prior diagnosis of diabetes or elevated fasting glucose level (≥ 100 mg/dL). Among 296 newly diagnosed BC cases and 259 healthy controls, multivariable logistic regression models were utilized to estimate adjusted odds ratios (aOR) and 95% confidence intervals (95% CI) for the association between MetS and BC overall. Multinomial logistic regression models were used to evaluate each molecular subtype (Luminal A, Luminal B, HER2-enriched and triple-negative or TNBC) | ||
| 520 | |a RESULTS: After adjusting for age, socio-demographic and reproductive risk factors, there was a positive association between MetS and BC (aOR: 1.84, 95% CI: 1.07, 3.16). In stratified analyses, MetS was associated with BC regardless of BMI status; however, the estimate was significant only among normal weight women (aOR: 3.85; 95% CI: 1.25, 11.90). MetS was significantly associated with TNBC subtype (aOR: 4.37, 95% CI: 1.67, 11.44); associations for other molecular subtypes were not statistically significant | ||
| 520 | |a CONCLUSION: MetS appears to be a robust risk factor for BC, particularly for TNBC. Public health and clinical interventions can provide substantial benefits in reducing the burden of MetS and preventing BC among Nigerian women | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Cholesterol | |
| 650 | 4 | |a Diabetes | |
| 650 | 4 | |a Hypertension | |
| 650 | 4 | |a Nigeria | |
| 650 | 4 | |a Triple-negative breast cancer | |
| 700 | 1 | |a Oyekunle, Taofik |e verfasserin |4 aut | |
| 700 | 1 | |a Salako, Omolola |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Anjali |e verfasserin |4 aut | |
| 700 | 1 | |a Alatise, Olusegun |e verfasserin |4 aut | |
| 700 | 1 | |a Ogun, Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Adeniyi, Adewale |e verfasserin |4 aut | |
| 700 | 1 | |a Deveaux, April |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, Allison |e verfasserin |4 aut | |
| 700 | 1 | |a Ayandipo, Omobolaji |e verfasserin |4 aut | |
| 700 | 1 | |a Olajide, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Olasehinde, Olalekan |e verfasserin |4 aut | |
| 700 | 1 | |a Arowolo, Olukayode |e verfasserin |4 aut | |
| 700 | 1 | |a Adisa, Adewale |e verfasserin |4 aut | |
| 700 | 1 | |a Afuwape, Oludolapo |e verfasserin |4 aut | |
| 700 | 1 | |a Olusanya, Aralola |e verfasserin |4 aut | |
| 700 | 1 | |a Adegoke, Aderemi |e verfasserin |4 aut | |
| 700 | 1 | |a Tollefsbol, Trygve O |e verfasserin |4 aut | |
| 700 | 1 | |a Arnett, Donna |e verfasserin |4 aut | |
| 700 | 1 | |a Muehlbauer, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Newgard, Christopher B |e verfasserin |4 aut | |
| 700 | 0 | |a H3 Africa Kidney Research Network |e verfasserin |4 aut | |
| 700 | 1 | |a Daramola, Adetola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical breast cancer |d 2000 |g 22(2022), 4 vom: 15. Juni, Seite e463-e472 |w (DE-627)NLM11782898X |x 1938-0666 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:4 |g day:15 |g month:06 |g pages:e463-e472 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clbc.2021.11.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 4 |b 15 |c 06 |h e463-e472 | ||